The global Gaucher disease treatment market is anticipated to grow at a considerable CAGR of around 3% during the forecast period. Gaucher disease is a type of genetic disease caused by mutation of cells that leads to one of the enzymes in the body not working properly. The body constantly recycles itself as old cells die and new cells are made There is a long list of enzymes that are responsible for the recycling dead cells, one of which when it’s not working properly leads to Gaucher disease. Gaucher disease has a lot of different symptoms out of which the most common is an enlarged liver and spleen. Currently, quite a lot of research is going on in the field regarding the treatment of Gaucher disease, which in turn, fuelling the growth of the Gaucher disease treatment market.
To Request a Sample of our Report on Gaucher Disease Treatment Market: https://www.omrglobal.com/request-sample/gaucher-disease-treatment-market
However, the SBT causes any adverse reaction in patients ranging from weight loss, tremor, flatulence, abdominal pain, dyspepsia, paresthesia, influenza-like symptoms, visual disturbances, and thrombocytopenia which is lowering the popularity of SBT in the Gaucher disease market. In addition, the high cost associated with the treatment is limiting the growth of the global Gaucher disease treatment market. For instance, according to the National Institute of Health in 2018, the average wholesale prices of ERTs are $1,903 per vial for imiglucerase (400 units), $1,652 per vial for velaglucerase (400 units), and $935 per vial for taliglucerase (200 units). Patients are often administered 60 units/kg every two weeks. As this dosage, the approximate annual costs for imiglucerase, velaglucerase, and taliglucerase would be $544,260, $472,475, and $510,510, respectively.
(Get 15% Discount on Buying this Report)
A full Report of Gaucher Disease Treatment Market is Available at: https://www.omrglobal.com/industry-reports/gaucher-disease-treatment-market
Gaucher Disease Treatment Market Segmentation
By Disease Type
- Type I
- Type II
- Type III
By Treatment Type
- Enzyme Replacement Therapy (ERT)
- Substrate Reduction Treatment (SBT)
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
